HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Business News: Dermapharm Gets Boost From Vitamin D; Sanofi Plans Turkish Launch; Krka Posts Sales RIse

Executive Summary

A round-up of European consumer health business news: Dermapharm sees 2021 sales rise on the back of increased vitamin D demand; Sanofi plans to launch Enzymatica's ColdZyme in Turkey; and Slovenia's Krka posts rise in OTC sales.

You may also be interested in...



Euro Q1 Consumer Health Earnings Preview: Sanofi, Reckitt, GSK And Bayer

Major Europe-based consumer health players Sanofi, Reckitt, GSK and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2022 results over the coming weeks.

Sanofi Not Distracted By M&A Chatter As It Gets Back On Par With Market Growth

Recent market interest shown in other OTC assets will not distract Sanofi from its long-term plan to overhaul its Consumer Healthcare business, says CEO Paul Hudson. And this plan is delivering results, with Sanofi back on par with the consumer health market, posting sales up by 5% in 2021.

German OTC Marketing Round-Up: Allergy Launches From Novartis, Hevert, Dermapharm And Bencard

OTC marketing news from Germany: A hard-won desloratadine launch from Novartis, two new products from Dermapharm, as well as homeopathic and probiotic alternatives from Hevert and Bencard. 

Related Content

Topics

UsernamePublicRestriction

Register

RS152434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel